Einstein-Invented Compound Now Being Tested in COVID-19 Clinical Trial

April 28, 2020—(BRONX, NY)—A compound originally discovered byAlbert Einstein College of Medicine’sVern Schramm, Ph.D., is being evaluated by BioCryst Pharmaceuticals, Inc., in Brazil as a treatment for COVID-19 patients. The randomized, double-blind, placebo-controlled trial is funded by the National Institute of Allergy and Infectious Diseases.
Source: Einstein News - Category: Universities & Medical Training Source Type: news